Tazeen Ahmad Analyst Performance

Managing Director at Bank of America

Tazeen Ahmad is a stock analyst at Bank of America in the medical sector, covering 28 publicly traded companies. Over the past year, Tazeen Ahmad has issued 34 stock ratings, including buy, hold, and sell recommendations. While full access to Tazeen Ahmad's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tazeen Ahmad's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 60 Last 10 Years
Buy Recommendations: 61.67% 37 Buy Ratings
Companies Covered: 28 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	61.7%	37 ratings
Hold	21.7%	13 ratings
Sell	16.7%	10 ratings

Out of 60 total stock ratings issued by Tazeen Ahmad at Bank of America, the majority (61.7%) have been Buy recommendations, followed by 21.7% Hold and 16.7% Sell.

Best & Worst Calls

Best Call
000.0%
GWPH
Mar 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
AMAM
Jul 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	89.3% of companies on NASDAQ	25 companies
NYSE	10.7% of companies on NYSE	3 companies

Tazeen Ahmad, an analyst at Bank of America, currently covers 28 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 28 companies	100.0%

Tazeen Ahmad of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 18 companies	64.3%
PHARMACEUTICAL PREPARATIONS 4 companies	14.3%
MED - DRUGS 3 companies	10.7%
MED - GENERIC DRG 1 company	3.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	3.6%
BIOTECHNOLOGY 1 company	3.6%

About Tazeen Ahmad

Tazeen Ahmad is a Managing Director in US Equity Research covering small and mid-cap Biotechnology. She joined the firm in 2009 as an associate on the large-cap pharmaceuticals team and transitioned to biotech in 2010. She assumed the role of senior SMID Biotech analyst in 2015. She has consistently ranked at the top of the II poll in smid biotech since 2017. Previously, she was an associate at Citigroup on the large-cap pharma team. She has a bachelor’s degree in biology from Harvard University and is based in New York.

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ALNY Alnylam Pharmaceuticals	9/17/2025	Boost Price Target	$462.37	$520.00	Buy
INCY Incyte	9/4/2025	Boost Price Target	$85.57	$104.00	Buy
ASND Ascendis Pharma A/S	9/2/2025	Boost Price Target	$201.91	$230.00	Buy
ARGX argenx	9/2/2025	Boost Price Target	$705.29	$887.00	Buy
PTCT PTC Therapeutics	8/20/2025	Lower Price Target	$49.59	$76.00	Buy
SRPT Sarepta Therapeutics	8/20/2025	Boost Price Target	$20.18	$17.00	Underperform
BNTX BioNTech	8/5/2025	Boost Price Target	$110.04	$134.00	Buy
PTCT PTC Therapeutics	7/29/2025	Boost Price Target	$49.02	$84.00	Buy
SRPT Sarepta Therapeutics	7/23/2025	Reiterated Rating	$13.61		Underperform
SRPT Sarepta Therapeutics	7/18/2025	Lower Price Target	$18.20	$20.00	Neutral
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
APLS Apellis Pharmaceuticals	7/16/2025	Boost Price Target	$19.35	$24.00	Neutral
BNTX BioNTech	7/16/2025	Lower Price Target	$110.65	$126.00	Buy
ALNY Alnylam Pharmaceuticals	7/11/2025	Boost Price Target	$322.64	$359.00	Buy
TSHA Taysha Gene Therapies	7/11/2025	Initiated Coverage	$2.55	$8.00	Buy
RYTM Rhythm Pharmaceuticals	7/10/2025	Boost Price Target	$88.44	$95.00	Buy
BCRX BioCryst Pharmaceuticals	7/1/2025	Boost Price Target	$9.00	$15.00	Buy
SRPT Sarepta Therapeutics	6/16/2025	Reiterated Rating	$18.52	$28.00	Neutral
ASND Ascendis Pharma A/S	6/9/2025	Boost Price Target	$174.41	$216.00	Buy
ACAD ACADIA Pharmaceuticals	6/5/2025	Boost Price Target	$21.77	$23.00	Hold
ASND Ascendis Pharma A/S	6/3/2025	Boost Price Target	$175.69	$201.00	Buy
PRTA Prothena	5/28/2025	Reiterated Rating	$4.58		Underperform
STRO Sutro Biopharma	5/19/2025	Lower Price Target	$0.86	$0.80	Underperform
DNLI Denali Therapeutics	5/19/2025	Lower Price Target	$13.90	$27.00	Buy
PTCT PTC Therapeutics	5/9/2025	Upgrade	$42.54	$68.00	Buy
APLS Apellis Pharmaceuticals	5/9/2025	Downgrade	$17.88	$23.00	Neutral
RYTM Rhythm Pharmaceuticals	4/7/2025	Upgrade	$52.80	$63.00	Buy
ALNY Alnylam Pharmaceuticals	3/21/2025	Boost Price Target	$253.60	$325.00	Buy
STRO Sutro Biopharma	3/14/2025	Downgrade	$1.25	$1.00	Underperform
ARVN Arvinas	3/12/2025	Lower Price Target	$8.30	$28.00	Buy
PTCT PTC Therapeutics	3/11/2025	Upgrade	$52.49	$55.00	Neutral
MRUS Merus	3/10/2025	Lower Price Target	$45.98	$70.00	Buy
FDMT 4D Molecular Therapeutics	3/10/2025	Lower Price Target	$3.92	$40.00	Buy
DNLI Denali Therapeutics	3/10/2025	Lower Price Target	$15.17	$28.00	Buy
NBIX Neurocrine Biosciences	2/7/2025	Lower Price Target	$150.51	$179.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.